Amyris, Inc. (NASDAQ:AMRS) Short Interest Up 6.9% in February

Amyris, Inc. (NASDAQ:AMRS – Get Rating) saw a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 51,680,000 shares, an increase of 6.9% from the February 13th total of 48,350,000 shares. Currently, 21.0% of the shares of the company are sold short. Based on an average daily volume of 5,870,000 shares, the days-to-cover ratio is presently 8.8 days.

Institutional Investors Weigh In On Amyris

Several hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its holdings in Amyris by 2.7% in the first quarter. BlackRock Inc. now owns 21,667,736 shares of the biotechnology company’s stock valued at $94,470,000 after purchasing an additional 575,957 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Amyris by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 19,793,472 shares of the biotechnology company’s stock worth $57,797,000 after purchasing an additional 712,965 shares during the last quarter. State of Michigan Retirement System raised its position in shares of Amyris by 6.3% during the 4th quarter. State of Michigan Retirement System now owns 7,645,000 shares of the biotechnology company’s stock worth $11,697,000 after purchasing an additional 450,000 shares during the last quarter. Edmond DE Rothschild Holding S.A. raised its position in shares of Amyris by 4.7% during the 3rd quarter. Edmond DE Rothschild Holding S.A. now owns 7,293,700 shares of the biotechnology company’s stock worth $21,298,000 after purchasing an additional 328,000 shares during the last quarter. Finally, State Street Corp raised its holdings in Amyris by 6.9% in the 3rd quarter. State Street Corp now owns 4,383,740 shares of the biotechnology company’s stock valued at $12,801,000 after acquiring an additional 283,546 shares during the last quarter. 43.08% of the stock is owned by hedge funds and other institutional investors.

Amyris Trading Down 3.8 %

Shares of AMRS stock opened at $1.27 on Friday. The company has a market cap of $419.30 million, a PE ratio of -0.72 and a beta of 1.10. Amyris has a 12-month low of $0.99 and a 12-month high of $5.15. The business’s fifty day simple moving average is $1.45 and its 200-day simple moving average is $2.10.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. StockNews.com assumed coverage on Amyris in a research report on Friday. They set a “sell” rating for the company. HC Wainwright dropped their target price on Amyris from $22.00 to $5.00 in a research report on Thursday. Finally, Piper Sandler dropped their target price on Amyris from $2.00 to $1.50 in a research report on Thursday. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $4.63.

Amyris Company Profile

(Get Rating)

Amyris, Inc engages in the provision of bioscience solutions. It offers its products to the health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.